Stay updated with breaking news from Will Alaynick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NanoCellect Biomedical, Inc. brought in $35 million in Series C and D funding to advance its microfluidic cell sorting solutions. Local investors such as FusionX Ventures, Anzu Partners and Agilent Technologies are among those backing the San Diego biotech.
NanoCellect Biomedical Reinvents the Cell Sorter with the WOLF G2 Expanded capabilities for a broader set of scientific applications News provided by Share this article Share this article SAN DIEGO, May 13, 2021 /PRNewswire/ -- NanoCellect Biomedical, a leader in the development of cell sorting, announces the virtual launch, scheduled for May 18, 2021, of the WOLF G2 Cell Sorter, the newest addition to NanoCellect's family of products. The WOLF G2 features simple and sterile cell sorting. This versatile system is ideally suited for use in cutting-edge research in academic and biopharma labor...